Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases

Arthritis Care and Research

Volumn 65, Issue 7, 2013, Pages 1085-1094

  Kawai, Vivian K ^a   Grijalva, Carlos G ^a   Arbogast, Patrick G ^f   Curtis, Jeffrey R ^b   Solomon, Daniel H ^c   Delzell, Elizabeth ^b   Chen, Lang ^b   Ouellet Hellstrom, Rita ^d   Herrinton, Lisa ^e   Liu, Liyan ^e   Mitchell, Edward F ^a   Stein, C Michael ^a   Griffin, Marie R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e KAISER PERMANENTE   (United States)

^f VA Tennessee Valley Health Care System ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; ENTERITIS; FRACTURE; HAZARD RATIO; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; OUTCOME ASSESSMENT; PELVIS FRACTURE; PROPENSITY SCORE; PSORIASIS; PSORIATIC ARTHRITIS; RADIUS FRACTURE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; ULNA FRACTURE;

EID: 84879731513     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21937     Document Type: Article

References (50)

1. Weiss RJ, Wick MC, Ackermann PW, Montgomery SM,. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases: a case-control study with 53,108 patients with fracture. J Rheumatol 2010; 37: 2247-50.
2. Huusko TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R,. Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis 2001; 60: 521-2.
3. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK,. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000; 43: 522-30.
4. Cooper C, Coupland C, Mitchell M,. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54: 49-52.
5. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12: R154.
6. Hooyman JR, Melton LJ III, Nelson AM, O'Fallon WM, Riggs BL,. Fractures after rheumatoid arthritis: a population-based study. Arthritis Rheum 1984; 27: 1353-61.
7. Van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C,. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 3104-12.
8. Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, et al. Bone, inflammation, and inflammatory bowel disease [review]. Curr Osteoporos Rep 2011; 9: 251-7.
9. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G,. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 2008; 93: 1952-8.
10. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ,. TNFα potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002; 143: 1108-18.
11. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-86.
12. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-α. Endocrinology 2000; 141: 3956-64.
13. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002; 110: 1419-27.
14. Barnabe C, Hanley DA,. Effect of tumor necrosis factor α inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy [review]. Semin Arthritis Rheum 2009; 39: 116-22.
15. Veerappan SG, O'Morain CA, Daly JS, Ryan BM,. Effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease [review]. Aliment Pharmacol Ther 2011; 33: 1261-72.
16. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P,. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 2007; 9: R61.
17. Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M,. Bone metabolism changes during anti-TNF-α therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069: 420-7.
18. Visvanathan S, van der HD, Deodhar A, Wagner C, Baker DG, Han J, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 175-82.
19. Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP,. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009; 68: 373-6.
20. Haugeberg G, Conaghan PG, Quinn M, Emery P,. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone: explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2009; 68: 1898-901.
21. Lange U, Teichmann J, Muller-Ladner U, Strunk J,. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005; 44: 1546-8.
22. Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheumatol 2007; 34: 303-10.
23. Ray WA, Griffin MR, Fought RL, Adams ML,. Identification of fractures from computerized Medicare files. J Clin Epidemiol 1992; 45: 703-14.
24. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG,. Identification and validation of vertebral compression fractures using administrative claims data. Med Care 2009; 47: 69-72.
25. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
26. Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, et al. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf 2011; 20: 1199-209.
27. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9.
28. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 353-7.
29. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF312μB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1495-9.
30. Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G,. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis 2009; 68: 1171-6.
31. Hoff M, Kvien TK, Kalvesten J, Elden A, Kavanaugh A, Haugeberg G,. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord 2011; 12: 54.
32. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68: 330-6.
33. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH,. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol 2009; 15: 155-60.
34. Kim SY, Schneeweiss S, Liu J, Solomon DH,. Effects of disease-modifying antirheumatic drugs on non-vertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res 2012; 27: 789-96.
35. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C,. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383-9.
36. Kawai V, Grijalva CG, Arbogast P, Curtis JR, Solomon DH, Delzell E, et al. Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63: 1415-24.
37. Mauro M, Radovic V, Armstrong D,. Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. Can J Gastroenterol 2007; 21: 637-42.
38. Bernstein M, Irwin S, Greenberg GR,. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 2005; 100: 2031-5.
39. Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR,. The effect of anti-TNF-α therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci 2006; 1068: 543-56.
40. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C,. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis 2003; 62: 347-9.
41. Kang KY, Lee KY, Kwok SK, Ju JH, Park KS, Hong YS, et al. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine 2011; 78: 188-93.
42. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, van Staa TP,. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007; 56: 208-14.
43. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al, and the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.
44. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, et al, and the Fosamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461-8.
45. McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004; 19: 728-36.
46. Masud T, McClung M, Geusens P,. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging 2009; 4: 445-9.
47. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
48. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al, and the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.
49. Schett G, David JP,. The multiple faces of autoimmune-mediated bone loss [review]. Nat Rev Endocrinol 2010; 6: 698-706.
50. Redlich K, Smolen JS,. Inflammatory bone loss: pathogenesis and therapeutic intervention [review]. Nat Rev Drug Discov 2012; 11: 234-50.